XYOSTED Feedback......

Discussion in 'Antares Pharma' started by anonymous, Dec 17, 2018 at 5:48 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    What is the medical community reception so far for Xyosted?
     

  2. anonymous

    anonymous Guest

    This time of year the docs are thinking about none medical issues you would imagine not much else. Although Xyosted is best in class, we shall see soon enough how they respond.
     
  3. anonymous

    anonymous Guest

    tough pull through with no coverage
    savings cards not enough incentive with much more affordable options available
     
  4. anonymous

    anonymous Guest

    Coverage will come in time. But I imagine the product profile is impressive to the doctors? They should view it as having advantages over the previous treatment options.
     
  5. anonymous

    anonymous Guest

    Might have a hard time selling with the FDA 483 to respond to...FDA was there and issued 483 December 2018.
     
  6. anonymous

    anonymous Guest

    wait.., did you say no insurance coverage?!?? How does this work, speciality pharmacy?
     
  7. anonymous

    anonymous Guest

    Can you provide a link to the form 483?
     
  8. anonymous

    anonymous Guest

    Great feedback so far and good initial uptake though anecdotal need too wait for script numbers/earnings. 483 poster reported to SEC.
     
  9. anonymous

    anonymous Guest

    Aim for Covering up to 70% of patients 1st year. So pretty good insurance coverage.
     
  10. anonymous

    anonymous Guest

    21 scripts?? Is it true?
    Any sales out there? Give us something
     
  11. anonymous

    anonymous Guest

    no way 70% coverage company too small no budget for coverage docs love the product but will not write because it’s not covered and have cheaper viable options
     
  12. anonymous

    anonymous Guest

    483 is fine no action determined by FDA
     
  13. anonymous

    anonymous Guest

    Yes way 70% coverage by EOY 2019. It is actually cheaper since the patient has less side effects and dr visits and better pk profile. Insurances will happily cover it.
     
  14. anonymous

    anonymous Guest

    Exactly! The drug is better for the patient - less emotional peaks and valleys due to the PK profile, patient self administers Sub Q at their own schedule at home without having to make needless office visits to get the standard IM dose. The physician can take care of more important issues than clog the office for a now non necessary office exercise (Administering IM Injections). The insurance carrier will saves money and administrative time every time the Docs Rx XYOSTED.

    XYOSTED is ideal for all! involved with testosterone treatment- It is a win win win......... :)
     
  15. anonymous

    anonymous Guest

    Also the testosterone gels are prehistoric tech compared to Xyosted. Apply the gel daily, waiting for it to dry, risk transferring testosterone to others, and having your clothes contaminated with testa. All more reason to use Xyosted sc.Another example why Xyosted is the best in class and why patients will use it first!
     
  16. anonymous

    anonymous Guest

    Looks like Xyosted is being received very well by the doctors. It could be a the market leader in the class.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    sure, haha funny.
    You must hold ATRS shares.....
    Seriously any sales want to comment?
     
  19. anonymous

    anonymous Guest

    The sounds of silence..........As they say no news is good news. The launch must be going well.
     
  20. anonymous

    anonymous Guest

    The prescriptions for Xyosted for the week ending 1/11/19 was 93. This is a fantastic number!
    Just launched a month ago during the year end Christmas and New Year Holidays with many people out of town, the response has been excellent. Expect this trend to accelerated significantly.